A new CRISPR tool utilizes Cas3 to remove larger than normal stretches of DNA both quickly and accurately. The tool, described in an October 19 article in Nature Methods, could help fill a void in current gene editing capabilities. Discuss
A research team has strengthened COVID-19 drug repurposing workflows through independent in vitro validation followed by clinical pharmacology data assessments, with the goal of launching clinical studies of currently approved drugs. The protocol was published in ACS Pharmacology & Translational Science on October 14. Discuss
Developing well-characterized adeno-associated viral vectors (AAVs) is a significant obstacle for the biomanufacturing industry. A group of analytical researchers is trying to overcome this challenge by developing novel analytical methodology specifically designed for AAVs. Discuss
A new retrospective study reveals that asymptomatic COVID-19 patients may have higher levels of lymphocytes, specifically T cells, compared to symptomatic COVID-19 patients despite carrying similar viral loads. The results were published in mSphere on October 7. Discuss
A new approach to RNA sequencing can enable scientists to extract 10 times more information from a single cell, including gene expression and subtle differences between healthy and diseased cells. The study, published in Immunity on October 13, reveals the power of the improved Seq-Well method and provides evidence of its efficacy in five inflammatory skin diseases. Discuss
In order to determine optimal cell growth conditions for the development of cellular therapies, researchers have devised an algorithm called EpiMorgify that can predict what factors are needed to produce high-quality cultures. The study was published on October 9 in Cell Systems. Discuss
Can antibodies developed against SARS-CoV during the 2003 outbreak be used to prevent infection by SARS-CoV-2? In an October 9 study published in Science Advances, researchers analyzed precious serum collected from convalescent SARS-CoV patients to find out. Discuss
Researchers have discovered that immunoglobulin G (IgG) antibodies to the SARS-CoV-2 virus are longer lasting in the blood and saliva of COVID-19 patients compared to the relatively short-lived IgM and IgA responses. The finding, presented in a pair of studies published in Science Immunology on October 8, suggests that IgG antibodies could be a promising target to detect and evaluate immune responses to the virus. Discuss
What impact will mutation of the SARS-CoV-2 virus have on the effectiveness of COVID-19 vaccines that are in development? In a new study published in NPJ Vaccines on October 8, Australian researchers say they believe that a recent change in the genetic material of the virus shouldn't reduce the effectiveness of vaccines coming to market. Discuss
The U.S. Food and Drug Administration (FDA) on October 6 issued a new guidance with recommendations for developers of COVID-19 vaccines regarding the scientific data and information that would be required to support emergency use authorization (EUA) for the products. Discuss
Insights
Exclusive content for Science Advisory Board members on trends and outcomes that are influencing the future of scientific research.
Communities
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Rewards
Earn points for contributing to research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Connect
